CClinicalTrials.gg
Sign In
Not yet recruitingNCT05759325Updated Mar 8, 2023

An Exploratory Study of ctDNA-MRD in Predicting the Efficacy of Esophageal Squamous Cell Carcinoma

An observational study in Squamous Cell Carcinoma of Esophagus, sponsored by Guangzhou Institute of Respiratory Disease. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-03-08.

Sponsored by Guangzhou Institute of Respiratory Disease · Observational

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to observe and evaluate the correlation between ctDNA-MRD and the therapeutic effect and prognosis of stage II-IVA operable esophageal squamous cell carcinoma.

Read the detailed description

ESCC patients with II-IVA resection will undergo MRD examination at the following time: the first examination is before the operation, the second examination is 7-10 days after the operation, and then 1 month after the operation, 2 weeks after the end of adjuvant treatment (if available), the follow-up period (every 3 months if there is no postoperative treatment) and the progress (the progress of the disease confirmed by the researcher), the patients will receive close MRD monitoring to evaluate the correlation between ctDNA-MRD and therapeutic efficacy and prognosis.

02

Conditions studied

  • Squamous Cell Carcinoma of Esophagus

Keywords

  • ESCC
  • ctDNA
03

In context

Carcinoma

6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.

This study's planned enrollment of 100 is below the median of 149 across 1,175 observational studies indexed under Carcinoma.

Browse Carcinoma studies →

Lead sponsor

Guangzhou Institute of Respiratory Disease is the lead sponsor of 96 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Esophageal squamous cell carcinoma patients who were initially diagnosed as stage II-IVA (TNM V8) and planned to undergo radical surgery

Inclusion criteria

  1. Patients with stage II-IVA Esophageal squamous cell carcinoma confirmed by clinical pathological staging;
  2. ≥18 years;
  3. Eastern Cooperative Oncology Group performance status score (ECOG PS) is 0 \~ 1 points;
  4. Expected survival time ≥ 6 months;
  5. Patients agree and have the ability to follow the planned study visits, laboratory tests and other research steps.

Exclusion criteria

Exclusion Criteria:

  1. Patients with other malignant tumors;
  2. Patient had undergone surgery before admission;
  3. Pregnant or lactating women;
  4. Patients with other serious diseases;
  5. Patients who could not understand the experiment content and could not cooperate with them and refused to sign the informed consent form;
  6. Patients with contraindications to radiotherapy and chemotherapy;
  7. Other researchers think it is not suitable.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Progression-free survival

    Evaluation of progression-free survival rate of esophageal squamous cell carcinoma patients with different MRD status during perioperative period

    Time frame: up to 2 year

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05759325
Lead sponsor
Guangzhou Institute of Respiratory Disease
Responsible party
Jun Liu (GuangzhouIRD, Guangzhou Institute of Respiratory Disease) — Principal investigator
First posted
Mar 8, 2023
Start date
Mar 2023 (estimated)
Primary completion
Mar 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 8, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Carcinoma→

Other studies from this sponsor

Guangzhou Institute of Respiratory Disease

Start the discussion